On November 12, Regeneron Pharmaceuticals rose 3.27% in regular trading, trading at $944.955/share, with turnover of $525 million.
The move coincided with continued market attention on the company’s liver-targeted siRNA program CIDEBsiRNA, whose early clinical data remained a key sentiment driver.
Recent disclosed data showed that after a single subcutaneous injection, liver fat was reduced by 58% to 80% at week 36 in a dose-dependent manner, versus a 2.9% decline in the placebo group. In addition, 93% of participants achieved at least a 30% reduction in liver fat, while ALT and AST indicators continued to improve. The latest regular-trading rise appears to reflect sustained investor focus on the program’s potential in metabolic dysfunction-associated fatty liver disease, following the company’s strong third-quarter results released in late October.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments